News and Insights

Pharmaceuticals and Medical Devices

Is Medicare Price Negotiation the Solution We Need?

Numerof Brief

On August 29th, the Biden Administration named the 10 drugs that will be subject to price negotiation with Medicare in the initial implementation of the Inflation Reduction Act (IRA) of 2022. Release of the list marked a milestone in a decades-long effort by Democrats to use the purchasing power of…

Transatlantic Perspectives on the Future of Pharma

For years, lawmakers have targeted the pharmaceutical industry, blaming it for the high cost of healthcare – its role in the management of Covid-19 notwithstanding.  Despite recent breakthroughs to rid the world of its worst scourges, both the U.S. and EU appear to regard pharma as the single worst actor…

The Numerof 2023 Global Pharma Outlook

Infographic

As our Numerof 2023 Global Pharma Outlook infographic illustrates, this year’s story for pharmaceutical manufacturers will be about continuing to adapt to pressures on price, especially mandated government negotiation, and demands for value while dealing with the long-term effects of the pandemic.

The Numerof 2023 Global Medical Device Outlook

Infographic

As our Numerof 2023 Global Medical Device Outlook infographic illustrates, this year’s story for medical device manufacturers will be about reconciling overhead inflation with market pressure on pricing, responding to demands for a data-based value narrative, and adjusting the commercialization process to an emerging post-pandemic reality.